Despite a curative treatment for hematological malignancy, allo-SCT is associated with many adverse effects in recipients. Weight loss occurs in 20-30% of patients after transplantation and is highly common among those with chronic GVHD (cGVHD). 1 The cGVHD scoring system associates severe weight loss with a poor prognosis. 1 The etiology of weight loss is not well understood at present, but is suspected to be multifactorial. Possible causes include malabsorption, decreased caloric intake, increased energy expenditure and hypercatabolism. 2 Weight loss may be partially due to pancreatic exocrine insufficiency as seen with steatorrhea 3, 4 or to gastrointestinal (GI) cGVHD. 5 To date, however, few reports have radiographically evaluated the pancreas of patients after SCT.
To evaluate pancreatic atrophy in long-term transplant survivors, we retrospectively reviewed consecutive 42 patients with hematological malignancy after allogeneic PBSCT from related donors at our institution between June 2001 and October 2007. All recipients had chest/abdominal computed tomography (CT) before transplantation. Eligible patients were those with at least 100-days' survival and had to be available for pancreatic assessment by CT anytime after PBSCT. Of them, 32 patients survived for more than 100 days. Two of the 32 patients were not available for CT assessment after PBSCT, leaving 30 patients eligible. GI involvement of acute GVHD and cGVHD was definitely diagnosed by endoscopic biopsy. Pancreatic atrophy was defined as volume loss of pancreatic appearance on CT compared between pre-and post-PBSCT. Weight loss was defined as the difference between baseline weight at transplantation (day 0±1 week) and minimum documented weight anytime after day 100. Factors for pancreatic atrophy were assessed by entering variables with a P-value of o0.05 into multivariable analysis using a logistic regression model.
The study population was primarily male (73%) and elderly (median 60 years; range: 23-73). Median observation duration of survivors was 3.8 years (range: 126-2664 days). In most patients (87%), PBSCs were from HLAmatched related donors. Twenty patients (67%) received fludarabine-based conditioning regimens. The reasons for CT assessment after day 100 post-PBSCT were as follows: 12 for assessment of pulmonary complications, 13 for detection of infection, 3 for disease follow-up and 2 for GVHD. Twenty-five patients had cGVHD including pulmonary complication. Sicca syndrome occurred most frequently in 14 (47%) and GI cGVHD occurred in 9 (30%). Five patients (17%) experienced less than 5% weight loss, 12 (40%) between 5 and 15% weight loss and 13 (43%) greater than 15% weight loss.
Of the 30 patients, steatorrhea was documented in one (3.3%) with pancreatic atrophy (patient 1), and this ratio was identical to another study. 4 The incidence of steatorrhea, however, might be underestimated because we did not test formally steatrrhea for all patients, and only two patients were unfortunately tested in patients with atrophy. Pancreatic atrophies occurred in 5 (16.7%) of the 30 patients (Table 1 and Figure 1 ). Each patient with pancreatic atrophy sometimes received CT scans after transplantation (median 14 times, range; 3-38), but pancreatic atrophy was not seen on any previous CT before the atrophy-documented day. In five patients with atrophy, no improvement was observed during follow-up. The reason for and the timing of CT assessment, however, were so varied that the detection was a chance event. Given this, the cumulative actual incidence of pancreatic atrophy could not be estimated. Patients with pancreatic atrophy had significantly more frequent cGVHD involving the liver (P ¼ 0.031) and GI tract (P ¼ 0.020) in the population, of which GI cGVHD remained significant in multivariative analysis (RR: 21.9 (95% CI: 1.2-383), P ¼ 0.035), suggesting that pancreatic atrophy might be a part of GI cGVHD. The GI cGHVD symptoms among atrophy patients were nausea and diarrhea in three, appetite loss in two and abdominal pain in one. The pathological findings of GI involvement were invasions of CD8 positive cells into epithelial cells and crypt degenerations. However, it was difficult to distinguish pancreatic atrophy after PBSCT from subclinical chronic pancreatitis because of lack of pancreatic functional test in the current study, although no calcifications or ductal dilatations were observed in any pancreases of these five patients. In previous autopsy studies of acute GVHD, the pancreas was considered a target organ of donor lymphocytes. 6, 7 The involvement of cGVHD in pancreas is necessary to be histopathologically confirmed.
Although no association with pancreatic atrophy was seen for the degree of weight loss (data not shown), maximum weight loss were documented nearly at the documented date of pancreatic atrophy in each case (Table 1) . So, pancreatic atrophy might be associated with the deterioration of weight loss in each case, although the degree was variable. Estimated 4-year OS were 48.4±9.4% in all 30 patients, 40.0±29.7% in patients with atrophy and 47.7±10.1% in patients without atrophy, respectively (P ¼ 0.67).
Bias in this analysis may have arisen from the retrospective aspect and from the small, high-risk study population because their median age was 60 years, although we analyzed consecutive day 100 survivors. This study, however, suggested that pancreatic atrophy was at least not a rare complication after PBSCT, particularly in those with GI cGVHD, and might be associated with the weight loss within each case.
Supplements of pancreatic enzymes are reported to be beneficial for recovery from steatorrhea. 4, 8 Although it remains unknown whether pancreatic enzyme supplements may be useful not only for patients with steatorrhea but also for patients with pancreatic atrophy with cGVHD, a Letter to the Editor prospective observation of routine pancreatic assessment and pancreatic enzyme supplements would be beneficial. In summary, 5 of the 30 long-term survivors of PBSCT experienced pancreatic atrophy, for which GI cGVHD was found to be an associated factor. CT imaging would be useful for an easy, reliable and non-invasive assessment for pancreatic abnormality. Pancreatic atrophy is not a rare complication after PBSCT. Further prospective observation of pancreatic atrophy is warranted to assess the actual incidence, risk factors and impact on clinical course.
